Passage Bio

Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease.

News

Penny Stocks

Pre-Market Outlook

Markets

Movers

Trading Ideas

ACON

ATAK

DUNE

EGIO

GMBL

ICCT

MESO

MGAM

Infrared Cameras Holdings, Inc. - Common Stock

MSAI

NOGN

PASG

PETV

PRZO

SXTP

VINO

Shares of  BlackBerry Limited  (NYSE: BB) moved lower in pre-market trading following the release of third-quarter results.

Why BlackBerry Shares Are Trading Lower By Over 5%; Here Are 20 Stocks Moving Premarket

Health Care

General

Passage Bio Inc (NASDAQ: PASG) announced initial safety and biomarker data from three Cohort 1 patients in the ongoing global Phase 1/2 upliFT-D clinical trial evaluating PBFT02, an adeno-associated virus (AAV)-delivery gene therapy for frontotemporal dementia (FTD) with 

Neurology-Focused Passage Bio Reveals Initial Data From Dementia Study, Outlines Strategic Priorities

Price Target

Analyst Ratings

AZPN

BNTX

CARA

MNDY

SGRY

SKIN

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page

Monday.Com To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Tuesday

Passage Bio Inc

Earnings

Press Releases

Passage Bio Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights

Passage Bio to Present at H.C. Wainwright 26th Annual Global Investment Conference

Management

Passage Bio Welcomes Tom Kassberg to Board of Directors

Passage Bio to Present Positive Interim Data from Cohort 1 Patients with FTD-GRN in upliFT-D Study at 14th International Conference on Frontotemporal Dementias (ISFTD2024)

Passage Bio to Present at Chardan's 8th Annual Genetic Medicines Conference

Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference

Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference

Passage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights

Passage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates

Passage Bio to Participate in Upcoming Investor Conferences

Abpro Hldgs

Allakos

Annovis Bio

Actinium Pharmaceuticals, Inc. (Delaware) Common Stock

Actinium Pharma

CASI Pharmaceuticals, Inc. - Ordinary Shares

CASI Pharmaceuticals

Celularity

Chemomab Therapeutics Ltd. - American Depositary Shares

Chemomab Therapeutics

Coeptis Therapeutics Holdings, Inc. - Common Stock

Coeptis Therapeutics

Curis

CEL-SCI

Cyclo Therapeutics

Elevation Oncology

Equillium

CytoMed Therapeutics Limited - Ordinary Shares

CytoMed Therapeutics

MiNK Therapeutics

Intensity Therapeutics, Inc. - Common Stock

Intensity Therapeutics

OS Therapies

Pluri

Q32 Bio

Rallybio

RenovoRx

Surrozen

Tempest Therapeutics, Inc. - Common Stock

Tempest Therapeutics

Unity Biotechnology

Exicure

Wedbush

Chardan Capital

Canaccord Genuity

Rodman & Renshaw

Raymond James

Comments

Passage Bio

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga